Click' Login' then 'Don't have an Account ' and join $$Lounge for free

Lexaria Corp CSE:LXX OTC:LXRP

More
1 year 5 months ago #118031 by alexgreat
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
This could be huge if it works

2017-05-10 09:31 ET - News Release

Mr. Chris Bunka reports

LEXARIA ANNOUNCES RESEARCH ON NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

Lexaria Bioscience Corp. plans to begin research and formulation development (R&D) on non-steroidal anti-inflammatory drugs (NSAIDs) utilizing its patented technology and as provisioned within its previously announced 2017 and 2018 R&D program.

Lexaria will conduct in vitro absorption studies utilizing the company's technology to examine improvements in absorption across human intestinal tissue, which is expected to be followed by in vivo (animal) studies to confirm the company's hypothesis regarding first-pass liver metabolism. The company postulates that its technology may enable oral delivery of NSAIDs without encountering first-pass liver metabolism, which has the potential to greatly reduce corresponding liver damage.

Pain relief drugs comprise mostly NSAIDs and opioids, and represented a $36.6-billion market in 2014. Long-term use or overuse of NSAIDs has been associated with chronic liver conditions that can be debilitating and even cause death.

Common generic forms of NSAIDS are products such as aspirin, ibuprofen, naproxen, diclofenac and others. Acetaminophen is sometimes included within this list. More effective absorption of NSAIDS may also lead to more effective pain killing properties, thus allowing for fewer opioid medication prescriptions. Prescription-based opioid medications are responsible for nearly 18,000 deaths annually in the United States.

Lexaria has a total of 18 patents pending -- including the delivery of NSAIDs -- and patent applications filed in more than 40 countries worldwide.

Please Log in or Create an account to join the conversation.

More
1 year 5 months ago #118003 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Nicotine could end up bigger for LXX than Canabis

Thursday May 4 2017 - News Release

Mr. Chris Bunka reports

LEXARIA ANNOUNCES R&D ON NICOTINE

Lexaria Bioscience Corp. plans to commence nicotine absorption research beginning in the summer of 2017, within its previously announced research and development budget that is fully funded.

Lexaria is developing leading technology for the more effective gastro-intestinal delivery of cannabinoids, vitamins, pain relievers, and other active molecules. Many active molecules are currently delivered in formats that are not conducive to human health and there is no better example than cigarette smoking that delivers nicotine.

Lexaria believes there are large and untapped markets available including for more efficient and healthy delivery of nicotine through edible products. In fact, nicotine administration in controlled studies has been found to be a potentially healthful molecule including in some studies shown to potentially be related to a decrease in incidence of Parkinson's disease. (University of Washington, Journal of Neuroscience)

Despite the fact that cigarette smoking is the leading cause of preventable death in the world (Euromonitor International and the World Health Organization) the global cigarette industry was worth $699 billion in 2015 with over 5.5 trillion cigarettes sold to over 1 billion customers. Current trends show that tobacco use will cause more than 8 million annual deaths by 2030. (Centers for Disease Control and Prevention)

In 2017 Lexaria will perform its first ever nicotine absorption studies utilizing human intestinal tissue in an in vitro environment, to determine whether Lexaria's technology assists in greater absorption of nicotine across the intestinal wall.

Positive 2017 results from Lexaria's in vitro nicotine testing would support the concept that an edible product containing nicotine could form an alternative to cigarettes as a nicotine delivery system. If successful, in vivo follow-up testing would be required to determine whether the Lexaria technology also aids in intestinal tolerance.

Lexaria currently has a total of 18 patents pending -- including for applying its technology to nicotine delivery -- and patent applications filed in more than 40 countries around the world.

Please Log in or Create an account to join the conversation.

More
1 year 6 months ago #117914 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Great news as they managed to close on a financing even when the stock weakened. US$0.42 is around C$0.55


Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce that it has completed its previously announced brokered private placement of 4,104,280 units of the Company ("Units") at a price per Unit of US$0.42 (the "Offering Price"), for total gross proceeds of US$1,723,798 (the "Offering").

Please Log in or Create an account to join the conversation.

More
1 year 6 months ago #117894 by alexgreat
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
The stock looks like a real good buy here

Please Log in or Create an account to join the conversation.

More
1 year 6 months ago #117876 by DearJohn
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Agree more great news, did you look into Philip Morris going with a smokeless cigarette?

""A few important steps are needed to make this common-sense approach a reality for millions of smokers. First, you need to invent less harmful alternatives to cigarettes. Second, these alternatives should be appealing to smokers: they should deliver a taste and sensory experience that leads smokers, who would otherwise continue to smoke, to switch. We can achieve a significant public-health benefit only when a large number of these smokers switch from cigarettes to better products.""

www.pmi.com/science-and-innovation/commo...ch-for-public-health

Please Log in or Create an account to join the conversation.

More
1 year 6 months ago #117872 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Been quiet here, some more good news

I think they have the goods, just have to get sales rolling


2017-03-22 09:32 ET - News Release

Mr. Chris Bunka reports

LEXARIA INTRODUCES TURBOCBD BRAND OF HIGH ABSORPTION FULL SPECTRUM HEMP OIL CAPSULES

Lexaria Bioscience Corp. has introduced the TurboCBD brand of technologically enhanced, high-absorption full-spectrum hemp oil capsules. Lexaria's TurboCBD capsules are specially formulated with the finest American ginseng and ginkgo biloba for support of enhanced focus and memory, and reduced stress and fatigue.

TurboCBD capsules utilize Lexaria's patented absorption technology and are triple tested for purity. They are made without the use of organic solvents and leave no hemp oil aftertaste. They are vegan, gluten free, sugar free, nut free and made in the United States. They will soon be offered for sale through California medical cannabis dispensaries and other select locations as the perfect complement to any cannabis regimen.

Lexaria's TurboCBD capsules are designed to work with the physiology of the human gastrointestinal system where minute quantities of long-chain fatty acids like sunflower oil, combined in each serving of TurboCBD capsules, are thoroughly and quickly absorbed into the circulatory system for maximum effectiveness. In vitro and human focus study testing has shown increases in cannabidiol (CBD) absorption using Lexaria's technology by as much as five to times more than conventional preparations. Those studies also demonstrated rapid onset of action in as little as 15 minutes.

Lexaria intends to showcase its TurboCBD capsules at the upcoming 2017 World Medical Marijuana Business Conference & Expo in Pittsburgh on April 21 and April 22, which is expected to attract over 8,000 cannabis professionals, including 1,200 physicians interested in the sector.

Lexaria is further researching other capsule formulations utilizing its patented absorption technology, each of which would be uniquely formulated to address specific market demands. Testing with Lexaria's technology has shown equally good improvements in enhancing absorption and rapidity of action when working with tetrahydrocannabinol (THC) as shown for CBD, and Lexaria continues to develop and seek opportunities to lever its technology for THC product applications through licensees in the U.S., Canada and internationally.

Please Log in or Create an account to join the conversation.

More
1 year 7 months ago #117768 by GoldnBoy
GoldnBoy replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
More good news today


Monday February 27 2017 - News Release

Mr. Chris Bunka reports

LEXARIA RECEIVES NOTICE OF ITS FIRST PATENT TO BE GRANTED IN AUSTRALIA FOR CANNABINOID INFUSED EDIBLES

Lexaria Bioscience Corp. has received a notice of acceptance from the Australian Patent Office that Lexaria's Australian patent application 2015274698 has been accepted with a patent issuance date expected in June, 2017. This establishes Lexaria's first successful acceptance for patent issuance outside of the United States, in what the company expects will be a series of successful international patent awards.

The notice of acceptance covers Lexaria's patent application entitled "Food and beverage compositions infused with lipophilic active agents and methods of use thereof," which has been accepted with the same set of claims previously issued in U.S. patent No. 9,474,725 specific to non-psychoactive cannabinoids.

Lexaria is very pleased with the rapid advancement of its patent claims by the Australian Patent Office and notes Australia's recent federal legislative success in opening the medical cannabis market. Like Canada, the medical cannabis market in Australia is federally legal.

"Lexaria's technology is needed not just in the U.S. but throughout the global cannabis sector, which is why we have patent applications in place in 42 countries around the world," said Chris Bunka, chief executive officer. "Our international applications offer the safety of unparalleled diversification to our supporters that even individual national market leaders cannot offer."

The accepted patent application includes a series of Lexaria's method claims for combining non-psychoactive cannabinoid lipophilic active agents together with a bioavailability and taste-enhancing oil by way of dehydration or lyophilization, and doing so in contact with a food product substrate material. Lexaria still has a number of additional patent applications undergoing review by the U.S. Patent and Trademark Office and patent application continuations planned in order to further broaden its expected set of compositional and method patent claims regarding the technology for application with other molecules such as psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs and nicotine.

The company continues to thank its many supporters who have contributed to its intellectual property success.

Please Log in or Create an account to join the conversation.

More
1 year 7 months ago #117707 by DearJohn
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Stock hanging in there nice, looks to be making a good base for next run

Please Log in or Create an account to join the conversation.

More
1 year 8 months ago #117663 by Gambler
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Great news, it seems every news release gets better, surprised this stock is still so cheap when you look at the others in the sector

Please Log in or Create an account to join the conversation.

More
1 year 8 months ago #117655 by GoldnBoy
GoldnBoy replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
lynnsa, agree, very good news. I just added to my position few days ago so it can continue higher now

Please Log in or Create an account to join the conversation.

More
1 year 8 months ago #117649 by lynnsa10
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Great news today

2017-02-08 10:14 ET - News Release


Mr. Chris Bunka reports

LEXARIA SIGNS MASTER COLLABORATIVE RESEARCH AGREEMENT

Lexaria Bioscience Corp., through its wholly owned Canadian subsidiary Lexaria Canpharm Corp., has signed and entered a master collaborative research agreement with the National Research Council of Canada (NRC) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions.

Lexaria believes that results from this scientific collaboration could motivate licence adoption of Lexaria's patented flavour masking and nutrient delivery enhancement technology, including but not limited to the vitamin, pain reliever and nicotine sectors. Lexaria's technology is patented in the United States, and patent pending in Canada and in 41 other countries around the world.

Under the agreement, Lexaria and the NRC will both provide up to $125,000 for this research, a total investment of up to $250,000. The master research agreement has an 18-month term, during which a number of shorter-term studies will be undertaken. The collaboration will investigate and define the chemical nature of the molecular association that Lexaria's patented technology is believed to effectuate between lipophilic active agents and fatty acids as solubility and bioavailability enhancing agents. Effective delivery of lipophilic active agents spans across industry sectors such as food, vitamins, pharmacy and more, which are multibillion-dollar opportunities.

Prospective lipophilic active agents to be investigated under the research agreement include cannabinoids (such as cananbidiol (CBD) and tetrahydrocannabinol (THC), fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine, as described in Lexaria's issued and pending patent applications, as well as potentially other high-value bioactives to be determined. The research agreement also provides for possible licensing of any arising, non-competing Lexaria intellectual property to the NRC or its sublicensees on terms to be defined in the future as applicable.

"This co-funded research agreement with the National Research Council of Canada is a major achievement for us," said John Docherty, president of Lexaria. "Having the privilege to work within their high-calibre facilities alongside their expert scientists will allow Lexaria to further advance the characterization and commercial potential of its technology in the fastest way possible for a company of our size. Furthermore, the fact that they have a level 2 dealer's licensed facility in Canada, in which some of this work can be conducted, is of particular importance, thereby allowing us to advance research on controlled substances with ease."

"The National Research Council's support in the development and commercialization of our technology is highly validating for our company," said Chris Bunka, chief executive officer of Lexaria. "Positive findings from this joint investigation will be of tremendous value to Lexaria in order to broaden the scientific understanding of our intellectual property suite and support our abilities to attract additional strategic licensees across the greater therapeutic foods, dietary supplements and pharmaceutical sectors."

Lexaria intends to commercialize its technology for widespread use by markets throughout the world, including over-the-counter pain remedy sector, vitamins and food supplements, and even the nicotine industries and more. To achieve that, this undertaking of fundamental research will enhance the company's ability to enter into these distinct market sectors.

Please Log in or Create an account to join the conversation.

More
1 year 8 months ago #117638 by DearJohn
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Yes I bought some more also.

Trump DOES NOT have an advisory group on Cannabis. Seems there is often in accurate media about Trump so posted this link


www.leafly.com/news/politics/da-group-re...ising-trump-cannabis

Please Log in or Create an account to join the conversation.

Time to create page: 0.344 seconds

Login Form